Current Environment: Production

Warning

Recall Alert

There is an antibacterial antibiotic recall. Read more

American Board of Pediatrics (General) | Education

Medical School

Medical University of Graz

Graz, Austria

Residency

Pediatrics

Boston Children's Hospital

Boston, MA

Fellowship

Pediatric Hematology/Oncology

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Boston, MA

American Board of Pediatrics (General) | Publications

  1. Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions. Nat Cancer. 2025 May 26. View Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions. Abstract

  2. Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. Cell Rep Med. 2025 May 20; 6(5):102095. View Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. Abstract

  3. Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell. 2025 Apr 14; 43(4):740-756.e8. View Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Abstract

  4. Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discov. 2025 Mar 03; 15(3):657. View Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Abstract

  5. Neuroimmune-competent human brain organoid model of diffuse midline glioma. Neuro Oncol. 2025 Feb 10; 27(2):369-382. View Neuroimmune-competent human brain organoid model of diffuse midline glioma. Abstract

  6. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2025 Feb 25; 217:115230. View Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Abstract

  7. Multi-omics approaches reveal that diffuse midline gliomas present altered DNA replication and are susceptible to replication stress therapy. Genome Biol. 2024 Dec 20; 25(1):319. View Multi-omics approaches reveal that diffuse midline gliomas present altered DNA replication and are susceptible to replication stress therapy. Abstract

  8. Applying single-cell and single-nucleus genomics to studies of cellular heterogeneity and cell fate transitions in the nervous system. Nat Neurosci. 2024 Dec; 27(12):2278-2291. View Applying single-cell and single-nucleus genomics to studies of cellular heterogeneity and cell fate transitions in the nervous system. Abstract

  9. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Cancer Cell. 2024 Aug 27. View GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Abstract

  10. Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling. Neuro Oncol. 2024 03 04; 26(3):553-568. View Diffuse midline glioma invasion and metastasis rely on cell-autonomous signaling. Abstract

  11. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology. Acta Neuropathol. 2024 01 24; 147(1):23. View Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology. Abstract

  12. An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Cell Rep. 2024 01 23; 43(1):113557. View An ERK5-PFKFB3 axis regulates glycolysis and represents a therapeutic vulnerability in pediatric diffuse midline glioma. Abstract

  13. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. 2024 01 08; 42(1):1-5. View A road map for the treatment of pediatric diffuse midline glioma. Abstract

  14. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discov. 2023 11 01; 13(11):2370-2393. View Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Abstract

  15. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Cancer Cell. 2023 11 13; 41(11):1911-1926.e8. View TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. Abstract

  16. Mapping pediatric brain tumors to their origins in the developing cerebellum. Neuro Oncol. 2023 10 03; 25(10):1895-1909. View Mapping pediatric brain tumors to their origins in the developing cerebellum. Abstract

  17. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Acta Neuropathol. 2023 09; 146(3):515-525. View A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4. Abstract

  18. Why haven't we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances. Neoplasia. 2023 05; 39:100895. View Why haven't we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances. Abstract

  19. Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods. Neuro Oncol. 2023 02 14; 25(2):234-247. View Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods. Abstract

  20. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. Acta Neuropathol Commun. 2023 02 09; 11(1):25. View Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. Abstract

  21. Neuronal-Activity Dependent Mechanisms of Small Cell Lung Cancer Progression. bioRxiv. 2023 Jan 20. View Neuronal-Activity Dependent Mechanisms of Small Cell Lung Cancer Progression. Abstract

  22. Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods. Neuro Oncol. 2023 Jan 05; 25(1):211. View Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods. Abstract

  23. Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Neuro Oncol. 2023 01 05; 25(1):54-67. View Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma. Abstract

  24. Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma. Neuro Oncol. 2023 01 05; 25(1):185-198. View Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma. Abstract

  25. The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Nat Genet. 2022 12; 54(12):1881-1894. View The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. Abstract

  26. BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. Cancer Discov. 2022 12 02; 12(12):2880-2905. View BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. Abstract

  27. VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022 10 10; 7(19). View VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. Abstract

  28. Immunotherapy approaches for the treatment of diffuse midline gliomas. Oncoimmunology. 2022; 11(1):2124058. View Immunotherapy approaches for the treatment of diffuse midline gliomas. Abstract

  29. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. Neuro Oncol. 2022 09 01; 24(9):1438-1451. View Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. Abstract

  30. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell. 2022 09 12; 40(9):957-972.e10. View A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Abstract

  31. An affinity for brainstem microglia in pediatric high-grade gliomas of brainstem origin. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac117. View An affinity for brainstem microglia in pediatric high-grade gliomas of brainstem origin. Abstract

  32. Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. Mol Cell. 2022 07 21; 82(14):2696-2713.e9. View Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. Abstract

  33. Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors. Pharmaceuticals (Basel). 2022 May 26; 15(6). View Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors. Abstract

  34. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022 03; 603(7903):934-941. View GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Abstract

  35. Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Sci Transl Med. 2021 Oct 06; 13(614):eabc0497. View Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Abstract

  36. Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathol. 2021 08; 142(2):339-360. View Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Abstract

  37. The imitation game: How glioblastoma outmaneuvers immune attack. Cell. 2021 04 29; 184(9):2278-2281. View The imitation game: How glioblastoma outmaneuvers immune attack. Abstract

  38. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 08; 68(8):e28930. View Outcomes after first relapse of childhood intracranial ependymoma. Abstract

  39. Understanding the epigenetic landscape and cellular architecture of childhood brain tumors. Neurochem Int. 2021 03; 144:104940. View Understanding the epigenetic landscape and cellular architecture of childhood brain tumors. Abstract

  40. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22. View Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Abstract

  41. Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas. Acta Neurochir (Wien). 2021 07; 163(7):2025-2035. View Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas. Abstract

  42. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262. View Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. Abstract

  43. Into Thin Air: Hypoxia Drives Metabolic and Epigenomic Deregulation of Lethal Pediatric Ependymoma. Dev Cell. 2020 07 20; 54(2):134-136. View Into Thin Air: Hypoxia Drives Metabolic and Epigenomic Deregulation of Lethal Pediatric Ependymoma. Abstract

  44. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun. 2020 07 14; 8(1):107. View Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Abstract

  45. Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Cancer Cell. 2020 07 13; 38(1):44-59.e9. View Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. Abstract

  46. The growing role of epigenetics in childhood cancers. Curr Opin Pediatr. 2020 02; 32(1):67-75. View The growing role of epigenetics in childhood cancers. Abstract

  47. Stalled developmental programs at the root of pediatric brain tumors. Nat Genet. 2019 12; 51(12):1702-1713. View Stalled developmental programs at the root of pediatric brain tumors. Abstract

  48. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell. 2019 11 11; 36(5):528-544.e10. View Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Abstract

  49. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. Mol Cell. 2019 12 19; 76(6):965-980.e12. View Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. Abstract

  50. Increasing value of autopsies in patients with brain tumors in the molecular era. J Neurooncol. 2019 Nov; 145(2):349-355. View Increasing value of autopsies in patients with brain tumors in the molecular era. Abstract

  51. Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements. Cell. 2019 09 19; 179(1):251-267.e24. View Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements. Abstract

  52. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731. View Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Abstract

  53. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 08; 572(7767):74-79. View Resolving medulloblastoma cellular architecture by single-cell genomics. Abstract

  54. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019 08 08; 178(4):835-849.e21. View An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Abstract

  55. Developmental origins and emerging therapeutic opportunities for childhood cancer. Nat Med. 2019 03; 25(3):367-376. View Developmental origins and emerging therapeutic opportunities for childhood cancer. Abstract

  56. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2018 06 28; 6(1):51. View Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Abstract

  57. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335. View Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Abstract

  58. Gliomas in Children. Semin Neurol. 2018 02; 38(1):121-130. View Gliomas in Children. Abstract

  59. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. Pharmacol Ther. 2018 02; 182:70-79. View Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. Abstract

  60. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Abstract

  61. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science. 2017 03 31; 355(6332). View Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Abstract

  62. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 2016 11 10; 539(7628):309-313. View Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Abstract

  63. Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. Annu Rev Pathol. 2016 05 23; 11:497-521. View Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. Abstract

  64. A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. J Vis Exp. 2015 Nov 07; (105):e53304. View A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. Abstract

  65. Of Brains and Blood: Developmental Origins of Glioma Diversity? Cancer Cell. 2015 Oct 12; 28(4):403-404. View Of Brains and Blood: Developmental Origins of Glioma Diversity? Abstract

  66. How neuronal activity regulates glioma cell proliferation. Neuro Oncol. 2015 Dec; 17(12):1543-4. View How neuronal activity regulates glioma cell proliferation. Abstract

  67. Metallothionein-I/II Promotes Axonal Regeneration in the Central Nervous System. J Biol Chem. 2015 Jun 26; 290(26):16343-56. View Metallothionein-I/II Promotes Axonal Regeneration in the Central Nervous System. Abstract

  68. Soluble adenylyl cyclase is necessary and sufficient to overcome the block of axonal growth by myelin-associated factors. J Neurosci. 2014 Jul 09; 34(28):9281-9. View Soluble adenylyl cyclase is necessary and sufficient to overcome the block of axonal growth by myelin-associated factors. Abstract

  69. PTEN inhibition enhances neurite outgrowth in human embryonic stem cell-derived neuronal progenitor cells. J Comp Neurol. 2014 Aug 15; 522(12):2741-55. View PTEN inhibition enhances neurite outgrowth in human embryonic stem cell-derived neuronal progenitor cells. Abstract

  70. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23. View Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Abstract

  71. Secretory leukocyte protease inhibitor reverses inhibition by CNS myelin, promotes regeneration in the optic nerve, and suppresses expression of the transforming growth factor-ß signaling protein Smad2. J Neurosci. 2013 Mar 20; 33(12):5138-51. View Secretory leukocyte protease inhibitor reverses inhibition by CNS myelin, promotes regeneration in the optic nerve, and suppresses expression of the transforming growth factor-ß signaling protein Smad2. Abstract

  72. Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats. Behav Brain Res. 2013 Apr 15; 243:66-73. View Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats. Abstract

  73. A novel role for PTEN in the inhibition of neurite outgrowth by myelin-associated glycoprotein in cortical neurons. Mol Cell Neurosci. 2011 Jan; 46(1):235-44. View A novel role for PTEN in the inhibition of neurite outgrowth by myelin-associated glycoprotein in cortical neurons. Abstract

  74. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer. 2010 May; 54(5):681-6. View Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Abstract

  75. A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway. J Neurosci. 2010 Jan 13; 30(2):739-48. View A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway. Abstract

  76. Combined intrinsic and extrinsic neuronal mechanisms facilitate bridging axonal regeneration one year after spinal cord injury. Neuron. 2009 Oct 29; 64(2):165-72. View Combined intrinsic and extrinsic neuronal mechanisms facilitate bridging axonal regeneration one year after spinal cord injury. Abstract

  77. Live or let die: CCM2 provides the link. Neuron. 2009 Sep 10; 63(5):559-60. View Live or let die: CCM2 provides the link. Abstract

  78. Increased synthesis of spermidine as a result of upregulation of arginase I promotes axonal regeneration in culture and in vivo. J Neurosci. 2009 Jul 29; 29(30):9545-52. View Increased synthesis of spermidine as a result of upregulation of arginase I promotes axonal regeneration in culture and in vivo. Abstract

  79. Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. Pediatr Blood Cancer. 2009 Apr; 52(4):476-80. View Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. Abstract

  80. Neurotrophin 3/TrkC-regulated proteins in the human medulloblastoma cell line DAOY. Electrophoresis. 2009 Feb; 30(3):540-9. View Neurotrophin 3/TrkC-regulated proteins in the human medulloblastoma cell line DAOY. Abstract

  81. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Clin Pharmacokinet. 2009; 48(4):265-71. View Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years. Abstract

  82. PirB, a second receptor for the myelin inhibitors of axonal regeneration Nogo66, MAG, and OMgp: implications for regeneration in vivo. Neuron. 2008 Dec 10; 60(5):740-2. View PirB, a second receptor for the myelin inhibitors of axonal regeneration Nogo66, MAG, and OMgp: implications for regeneration in vivo. Abstract

  83. Mitosis-dependent protein expression in neuroblastoma cell line N1E-115. J Proteome Res. 2008 Aug; 7(8):3412-22. View Mitosis-dependent protein expression in neuroblastoma cell line N1E-115. Abstract

  84. Synthesis, chaperoning, and metabolism of proteins are regulated by NT-3/TrkC signaling in the medulloblastoma cell line DAOY. J Proteome Res. 2008 May; 7(5):1932-44. View Synthesis, chaperoning, and metabolism of proteins are regulated by NT-3/TrkC signaling in the medulloblastoma cell line DAOY. Abstract

  85. BDNF activates CaMKIV and PKA in parallel to block MAG-mediated inhibition of neurite outgrowth. Mol Cell Neurosci. 2008 May; 38(1):110-6. View BDNF activates CaMKIV and PKA in parallel to block MAG-mediated inhibition of neurite outgrowth. Abstract

  86. The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Exp Neurol. 2008 Feb; 209(2):321-32. View The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury. Abstract

  87. The inhibition site on myelin-associated glycoprotein is within Ig-domain 5 and is distinct from the sialic acid binding site. J Neurosci. 2007 Aug 22; 27(34):9146-54. View The inhibition site on myelin-associated glycoprotein is within Ig-domain 5 and is distinct from the sialic acid binding site. Abstract

  88. Therapeutic approaches to promoting axonal regeneration in the adult mammalian spinal cord. Int Rev Neurobiol. 2007; 77:57-105. View Therapeutic approaches to promoting axonal regeneration in the adult mammalian spinal cord. Abstract

  89. Myelin-associated inhibitory signaling and strategies to overcome inhibition. J Cereb Blood Flow Metab. 2007 Jun; 27(6):1096-107. View Myelin-associated inhibitory signaling and strategies to overcome inhibition. Abstract

  90. Recapitulate development to promote axonal regeneration: good or bad approach? Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29; 361(1473):1565-74. View Recapitulate development to promote axonal regeneration: good or bad approach? Abstract

  91. How inflammation promotes regeneration. Nat Neurosci. 2006 Jun; 9(6):715-7. View How inflammation promotes regeneration. Abstract

  92. Nectin-like molecule 1 is a high abundance protein in cerebellar neurons. Amino Acids. 2006 Jun; 30(4):409-15. View Nectin-like molecule 1 is a high abundance protein in cerebellar neurons. Abstract

  93. The cytokine interleukin-6 is sufficient but not necessary to mimic the peripheral conditioning lesion effect on axonal growth. J Neurosci. 2006 May 17; 26(20):5565-73. View The cytokine interleukin-6 is sufficient but not necessary to mimic the peripheral conditioning lesion effect on axonal growth. Abstract

  94. The medulloblastoma cell line DAOY but not eleven other tumor cell lines expresses minichromosome maintenance protein 4. Cancer Lett. 2006 Jul 08; 238(1):76-84. View The medulloblastoma cell line DAOY but not eleven other tumor cell lines expresses minichromosome maintenance protein 4. Abstract

  95. MAG induces regulated intramembrane proteolysis of the p75 neurotrophin receptor to inhibit neurite outgrowth. Neuron. 2005 Jun 16; 46(6):849-55. View MAG induces regulated intramembrane proteolysis of the p75 neurotrophin receptor to inhibit neurite outgrowth. Abstract

  96. Overcoming inhibitors in myelin to promote axonal regeneration. J Neurol Sci. 2005 Jun 15; 233(1-2):43-7. View Overcoming inhibitors in myelin to promote axonal regeneration. Abstract

  97. Activated CREB is sufficient to overcome inhibitors in myelin and promote spinal axon regeneration in vivo. Neuron. 2004 Nov 18; 44(4):609-21. View Activated CREB is sufficient to overcome inhibitors in myelin and promote spinal axon regeneration in vivo. Abstract

  98. Expression of proteasomal proteins in ten different tumor cell lines. Amino Acids. 2004 Oct; 27(2):129-40. View Expression of proteasomal proteins in ten different tumor cell lines. Abstract

  99. Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury. J Neurosci. 2004 Jul 14; 24(28):6402-9. View Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury. Abstract

  100. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci U S A. 2004 Jun 08; 101(23):8786-90. View The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Abstract

  101. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med. 2004 Jun; 10(6):610-6. View cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Abstract

  102. A role for cAMP in regeneration of the adult mammalian CNS. J Anat. 2004 Jan; 204(1):49-55. View A role for cAMP in regeneration of the adult mammalian CNS. Abstract

  103. Neurotrophins elevate cAMP to reach a threshold required to overcome inhibition by MAG through extracellular signal-regulated kinase-dependent inhibition of phosphodiesterase. J Neurosci. 2003 Dec 17; 23(37):11770-7. View Neurotrophins elevate cAMP to reach a threshold required to overcome inhibition by MAG through extracellular signal-regulated kinase-dependent inhibition of phosphodiesterase. Abstract

  104. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci. 2003 Sep; 4(9):703-13. View Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Abstract

  105. New roles for old proteins in adult CNS axonal regeneration. Curr Opin Neurobiol. 2003 Feb; 13(1):133-9. View New roles for old proteins in adult CNS axonal regeneration. Abstract

  106. Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Neuron. 2002 Aug 15; 35(4):711-9. View Arginase I and polyamines act downstream from cyclic AMP in overcoming inhibition of axonal growth MAG and myelin in vitro. Abstract

  107. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron. 2002 Jul 18; 35(2):283-90. View Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Abstract

  108. Spinal axon regeneration induced by elevation of cyclic AMP. Neuron. 2002 Jun 13; 34(6):895-903. View Spinal axon regeneration induced by elevation of cyclic AMP. Abstract

  109. A role for cAMP in regeneration during development and after injury. Prog Brain Res. 2002; 137:381-7. View A role for cAMP in regeneration during development and after injury. Abstract

American Board of Pediatrics (General) | Education

Medical School

George Washington University Medical School

1997, Washington, DC

Internship

Children's National Medical Center

1998, Washington, DC

Residency

Children's National Medical Center

2000, Washington, DC

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Undergraduate School

Johns Hopkins University

Baltimore, MD

Graduate School

University of Cambridge

Cambridge, England

Medical School

Brown University

Providence, RI

Residency

Yale New Haven Hospital

New Haven, CT

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Medical School

Harvard Medical School

2006, Boston, MA

Internship

Boston Combined Residency Program (BCRP)

2007, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

2009, Boston, MA

Residency

Chief Resident

Boston Children's Hospital

2010, Boston, MA

Fellowship

Pediatric Emergency Medicine

Boston Children's Hospital

2013, Boston, MA

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Medical School

University of Chicago Pritzker School of Medicine

2005, Chicago, IL

Internship

Boston Combined Residency Program (BCRP)

2006, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

2008, Boston, MA

Residency

Anesthesiology

Johns Hopkins Hospital

2011, Baltimore, MD

Fellowship

Pediatric Critical Care

Johns Hopkins Hospital

2013, Baltimore, MD

Fellowship

Pediatric Anesthesiology

Johns Hopkins Hospital

2014, Baltimore, MD

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Undergraduate School

University of Alberta

2000, Edmonton, Alberta, Canada

Graduate School

MSc

University of Toronto

2001, Toronto, Ontario, Canada

Medical School

University of Alberta

2005, Edmonton, Alberta, Canada

Residency

Stollery Children's Hospital

2009, Edmonton, Alberta, Canada

Fellowship

Pediatric Cardiology

Boston Children's Hospital

2012, Boston, MA

Fellowship

Interventional Cardiology

Boston Children's Hospital

2013, Boston, MA

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Undergraduate School

Williams College

2005, Williamstown, MA

Medical School

University of Utah School of Medicine

2011, Salt Lake City, UT

Internship

Internal Medicine/Pediatrics

University of Utah School of Medicine

2012, Salt Lake City, UT

Residency

Pediatrics

University of Utah School of Medicine

2014, Salt Lake City, UT

Fellowship

Boston Children's Hospital

2018, Boston, MA

Graduate School

Harvard T.H. Chan School of Public Health

2018, Boston, MA

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Graduate School

Immunology

University of Oxford

2006, Oxford, United Kingdom

Medical School

Washington University School of Medicine

2008, St. Louis, MO

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

2011, Boston, MA

Fellowship

Critical Care

Boston Children's Hospital

2015, Boston, MA

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Undergraduate School

University of Michigan

1991, Ann Arbor, MI

Graduate School

MPH

Tufts University

1995, Boston, MA

Medical School

Tufts University School of Medicine

1995, Boston, MA

Residency

Boston Children's Hospital

1999, Boston, MA

Fellowship

Boston Children's Hospital

2003, Boston, MA

American Board of Pediatrics (General) | Publications

American Board of Pediatrics (General) | Education

Medical School

University of Massachusetts Medical School

2007, Worcester, MA

Internship

Boston Combined Residency Program (BCRP)

2008, Boston, MA

Residency

Boston Combined Residency Program (BCRP)

2010, Boston, MA

Residency

Chief Resident

Boston Combined Residency Program (BCRP)

2011, Boston, MA

Fellowship

Pediatric Emergency Medicine

Boston Children's Hospital

2014, Boston, MA

American Board of Pediatrics (General) | Publications

Talk to Lesley

If this is a medical emergency, please dial 9-1-1. This application should not be used in an emergency. This chat is being transmitted via a secure connection.

Hi! My name is Lesley. I am a virtual agent programmed to help you. If you would like to speak to a live agent, please call 617-355-6000.

I am unable to answer specific questions regarding your child's case, including appointments and conditions/diagnosis. Please contact your physician's office.

Quick links:

- MyChildrens Portal
- Global Services
- Find a Doctor
- Find a Location
- Programs and Services